What is the translation of " MIFAMURTID " in English?

• mifamurtide

Examples of using Mifamurtid in Croatian and their translations into English

Jedna bočica sadrži 4 mg mifamurtida.
One vial contains 4 mg mifamurtide.

Mifamurtid nije bio mutagen i nije pokazao teratogeno djelovanje kod štakora i kunića.
Mifamurtide was not mutagenic and did not cause teratogenic effects in rats and rabbits.

Svaka bočica sadrži 4 mg mifamurtida.
Each vial contains 4 mg of mifurtamide.

U preostalom vremenu ispitivanja, liječenje mifamurtidom nastavljeno je bez ponovne pojave konvulzija.
Mifamurtide treatment was continued for the remainder of the study without seizure recurrence.

Svaki ml rekonstituirane suspenzije sadrži 0, 08 mg mifamurtida.
Each ml reconstituted suspension contains 0.08 mg mifamurtide.

Djelatna tvar u lijeku Mepact, mifamurtid, je imunomodulator.
The active substance in Mepact, mifamurtide, is an immunomodulator.

Prašak za koncentrat za disperziju za infuziju 4 mg mifamurtida.
Powder for concentrate for dispersion for infusion 4 mg mifamurtide.

Ti podaci pokazuju da se ni ukupni niti slobodni mifamurtid ne akumuliraju tijekom razdoblja liječenja.
These data indicate that neither total nor free mifamurtide accumulated during the treatment period.

MEPACT 4 mg prašak za koncentrat za disperziju za infuziju mifamurtid.
MEPACT 4 mg powder for concentrate for dispersion for infusion Mifamurtide.

Hiperhidroza(11%) je bila vrlo česta kod bolesnika koji su mifamurtid primali u nekontroliranim ispitivanjima.
Hyperhidrosis(11%) was very common in patients receiving mifamurtide in uncontrolled studies.

Mifamurtid se ne preporučuje koristiti tijekom trudnoće niti u žena reproduktivne dobi koje ne koriste učinkovitu kontracepciju.
Mifamurtide is not recommended for use during pregnancy and in women of childbearing potential not using effective contraception.

Nisu provedena namjenska ispitivanja plodnosti povezana s mifamurtidom vidjeti dio 5.3.
No dedicated fertility studies have been conducted with mifamurtide see section 5.3.

MEPACT sadrži djelatnu tvar mifamurtid, sličnu sastojku stanične stijenke određenih bakterija.
MEPACT contains the active substance mifamurtide, similar to a component of the cell wall of certain bacteria.

Mifamurtid se može davati u razdobljima neutropenije, ali posljedičnu vrućicu koja se pripisuje liječenju treba pomno nadzirati.
Mifamurtide may be given during periods of neutropenia, but subsequent fever attributed to the treatment should be monitored closely.

Anemija je bila vrlo često prijavljivana kad se mifamurtid koristio istovremeno s kemoterapeuticima.
Anaemia has very commonly been reported when mifamurtide is used in conjunction with chemotherapeutic agents.

Primjena mifamurtida bila je često povezana s prolaznom neutropenijom, obično kad se je koristio istovremeno s kemoterapijom.
Administration of mifamurtide was commonly associated with transient neutropenia, usually when used in conjunction with chemotherapy.

Bol niske razine bila je vrlo česta kod bolesnika koji primaju mifamurtid, uključujući mijalgiju(31%), bol u leđima(15%), bol u ekstremitetima(12%) i artralgiju 10.
Low grade pain was very common in patients receiving mifamurtide, including myalgia(31%), back pain(15%), extremity pain(12%) and arthralgia 10.

Liječenje mifamurtidom treba započeti i nadzirati liječnik specijalist s iskustvom u dijagnosticiranju i liječenju osteosarkoma.
Mifamurtide treatment should be initiated and supervised by specialist physicians experienced in the diagnosis and treatment of osteosarcoma.

In vitro ispitivanja interakcija pokazala su da liposomalni i neliposomalni mifamurtid ne inhibira metaboličku aktivnost citokroma P450 u združenim ljudskim mikrosomima jetre.
In vitro interaction studies showed that liposomal and non-liposomal mifamurtide do not inhibit the metabolic activity of cytochrome P450 in pooled human liver microsomes.

Mifamurtid kao adjuvanta terapija značajno je produžio preživljavanje bez bolesti kod pasa s osteosarkomom i hemangiosarkomom.
Significant enhancement of disease-free survival was also demonstrated in the treatment of dog osteosarcoma and hemangiosarcoma with mifamurtide as adjuvant therapy.

Preporučuje se razdvojiti vrijeme primjene mifamurtida i doksorubicina ili drugih lipofilnih lijekova koji se koriste u istom režimu kemoterapije.
It is recommended to separate the administration times of mifamurtide and doxorubicin or other lipophilic medicinal products if used in the same chemotherapy regimen.

Mifamurtid je ispitivan kao jedini lijek u liječenju 248 bolesnika s pretežno uznapredovalim malignomima u ranom kliničkom ispitivanju faze I i II sa jednim krakom pacijenata.
Mifamurtide was studied as a single agent in 248 patients with mostly advanced malignancies during the early, single arm phase I and II clinical studies.

Gastrointestinalna toksičnost može biti pojačana kad se mifamurtid koristi u kombinaciji s visokim dozama polikemoterapije i povezana je s češćom primjenom parenteralne prehrane.
Gastrointestinal toxicity may be exacerbated when mifamurtide is used in combination with high dose, multi-agent chemotherapy and was associated with an increased use of parenteral nutrition.

Mifamurtid(muramil tripeptid fosfatidil etanolamin, MTP-PE) je potpuno sintetski derivat muramil dipeptida(MDP), najmanje imunostimulacijske komponente stanične stijenke Mycobacterium sp. koja se javlja u prirodi.
Mifamurtide(muramyl tripeptide phosphatidyl ethanolamine, MTP-PE) is a fully synthetic derivative of muramyl dipeptide(MDP), the smallest naturally-occurring immune stimulatory component of cell walls from Mycobacterium sp.

Šest sati nakon injiciranja radioaktivno označenih liposoma koji sadrže 1 mg mifamurtida, radioaktivnost je zabilježena u jetri, slezeni, nazofarinksu, štitnoj žlijezdi i u manjem opsegu u plućima.
At 6 hours after injection of radiolabelled liposomes containing 1 mg mifamurtide, radioactivity was found in liver, spleen, nasopharynx, thyroid, and, to a lesser extent, in lung.

S liječenjem mifamurtidom povezane su povremene alergijske reakcije, uključujući osip, nedostatak zraka i hipertenziju stupnja 4 vidjeti dio 4.8.
Occasional allergic reactions have been associated with mifamurtide treatment, including rash, shortness of breath and Grade 4 hypertension see section 4.8.

Nakon injiciranja radioaktivno označenih liposoma koji sadrže mifamurtid, srednja vrijednost poluvijeka radioaktivno označenog materijala bila je dvofazna sa α fazom od oko 15 minuta i terminalnim poluvijekom od približno 18 sati.
After injection of radiolabelled liposomes containing mifamurtide, mean half-life of radiolabelled material was biphasic with an α-phase of about 15 minutes and a terminal half-life of approximately 18 hours.

Mifamurtid je značajno povećao ukupno preživljenje bolesnika s novodijagnosticiranim resektabilnim osteosarkomom visokog stupnja malignosti kad se je koristio zajedno s kombinacijskom kemoterapijom u usporedbi sa samom kemoterapijom.
Mifamurtide significantly increased the overall survival of patients with newly-diagnosed resectable high-grade osteosarcoma when used in conjunction with combination chemotherapy when compared to chemotherapy alone.

In vivo primjena mifamurtida rezultirala je inhibicijom tumorskog rasta kod miševa i štakora s metastazama na plućima, s karcinomom kože i jetre te s fibrosarkomom.
In vivo administration of mifamurtide resulted in the inhibition of tumour growth in mouse and rat models of lung metastasis, skin and liver cancer, and fibrosarcoma.

Liposomalni i neliposomalni mifamurtid ne potiču metaboličku aktivnost ili transkripciju citokroma P450 u primarnim kulturama svježe izoliranih ljudskih hepatocita.
Liposomal and non-liposomal mifamurtide do not induce the metabolic activity or the transcription of cytochrome P450 in primary cultures of freshly isolated human hepatocytes.